MavriX Bio Receives FDA Fast Track Designation for MVX-220 for Treatment of Angelman Syndrome
Read the press release
MavriX Bio MVX-220 Update
MavriX Bio’s gene therapy MVX-220 receives FDA Fast Track designation, with its Phase 1/2 ASCEND-AS trial now listed and a community webinar set for October 9.